INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 184 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $241,002 | -55.8% | 12,399 | -74.8% | 0.00% | – |
| Q2 2023 | $544,915 | -6.1% | 49,269 | +14.0% | 0.00% | – |
| Q1 2023 | $580,364 | +13.8% | 43,214 | +3.6% | 0.00% | – |
| Q4 2022 | $510,000 | -59.0% | 41,700 | -53.2% | 0.00% | – |
| Q3 2022 | $1,244,000 | -5.3% | 89,193 | -6.2% | 0.00% | – |
| Q2 2022 | $1,314,000 | -7.3% | 95,111 | +9.2% | 0.00% | – |
| Q1 2022 | $1,418,000 | +12.1% | 87,121 | +12.1% | 0.00% | – |
| Q4 2021 | $1,265,000 | +314.8% | 77,693 | +278.5% | 0.00% | – |
| Q3 2021 | $305,000 | -65.4% | 20,525 | -53.5% | 0.00% | – |
| Q2 2021 | $881,000 | +63.1% | 44,118 | +88.5% | 0.00% | – |
| Q1 2021 | $540,000 | -98.2% | 23,409 | -98.1% | 0.00% | -100.0% |
| Q4 2020 | $29,900,000 | -16.3% | 1,210,532 | +40.6% | 0.01% | -26.7% |
| Q3 2020 | $35,709,000 | +345.8% | 861,278 | +415.1% | 0.02% | +400.0% |
| Q2 2020 | $8,010,000 | -68.0% | 167,198 | -57.9% | 0.00% | -76.9% |
| Q1 2020 | $24,995,000 | -24.5% | 397,034 | +48.6% | 0.01% | -7.1% |
| Q4 2019 | $33,115,000 | +155.4% | 267,230 | +36.8% | 0.01% | +133.3% |
| Q3 2019 | $12,968,000 | +28.6% | 195,412 | +53.9% | 0.01% | +20.0% |
| Q2 2019 | $10,087,000 | +160.5% | 126,984 | +266.3% | 0.01% | +150.0% |
| Q1 2019 | $3,872,000 | +11.4% | 34,671 | +0.5% | 0.00% | 0.0% |
| Q4 2018 | $3,477,000 | -47.6% | 34,511 | -34.3% | 0.00% | 0.0% |
| Q3 2018 | $6,637,000 | +86.5% | 52,514 | +23.9% | 0.00% | 0.0% |
| Q2 2018 | $3,558,000 | -35.3% | 42,401 | -52.5% | 0.00% | 0.0% |
| Q1 2018 | $5,498,000 | -38.0% | 89,348 | -41.1% | 0.00% | -50.0% |
| Q4 2017 | $8,869,000 | -89.5% | 151,782 | -89.5% | 0.00% | -90.0% |
| Q3 2017 | $84,192,000 | -73.0% | 1,450,512 | -43.7% | 0.04% | -74.4% |
| Q2 2017 | $311,971,000 | -4.6% | 2,576,729 | -10.9% | 0.16% | -7.7% |
| Q1 2017 | $326,920,000 | +20.0% | 2,890,542 | +15.3% | 0.17% | +13.4% |
| Q4 2016 | $272,483,000 | -37.0% | 2,507,900 | -4.5% | 0.15% | -38.4% |
| Q3 2016 | $432,212,000 | +0.8% | 2,626,000 | -12.6% | 0.24% | -3.6% |
| Q2 2016 | $428,935,000 | +13.9% | 3,006,293 | +2.5% | 0.25% | +11.6% |
| Q1 2016 | $376,679,000 | -11.9% | 2,932,040 | +2.4% | 0.22% | -10.4% |
| Q4 2015 | $427,601,000 | +39.6% | 2,863,069 | +55.0% | 0.25% | +32.1% |
| Q3 2015 | $306,234,000 | -15.2% | 1,846,894 | +23.4% | 0.19% | -7.8% |
| Q2 2015 | $361,123,000 | +55.5% | 1,496,079 | +81.6% | 0.21% | +54.9% |
| Q1 2015 | $232,271,000 | +1808.4% | 823,608 | +955.8% | 0.13% | +1800.0% |
| Q4 2014 | $12,171,000 | -43.2% | 78,005 | -13.9% | 0.01% | -46.2% |
| Q3 2014 | $21,435,000 | +48.2% | 90,559 | +48.1% | 0.01% | +44.4% |
| Q2 2014 | $14,465,000 | +143.7% | 61,128 | +239.6% | 0.01% | +125.0% |
| Q1 2014 | $5,936,000 | +455.3% | 18,002 | +15.0% | 0.00% | +300.0% |
| Q4 2013 | $1,069,000 | +29.1% | 15,649 | +30.4% | 0.00% | 0.0% |
| Q3 2013 | $828,000 | +4500.0% | 11,997 | +2968.3% | 0.00% | – |
| Q2 2013 | $18,000 | – | 391 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |